204 related articles for article (PubMed ID: 22342916)
1. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.
Sablan BP; Kim DJ; Barzaga NG; Chow WC; Cho M; Ahn SH; Hwang SG; Lee JH; Namini H; Heyward WL
Vaccine; 2012 Mar; 30(16):2689-96. PubMed ID: 22342916
[TBL] [Abstract][Full Text] [Related]
2. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
Janssen JM; Heyward WL; Martin JT; Janssen RS
Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.
Janssen JM; Jackson S; Heyward WL; Janssen RS
Vaccine; 2015 Jul; 33(31):3614-8. PubMed ID: 26067185
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.
Halperin SA; McNeil S; Langley JM; Smith B; MacKinnon-Cameron D; McCall-Sani R; Heyward WL; Martin JT
Vaccine; 2012 Aug; 30(36):5445-8. PubMed ID: 22704926
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
12. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
13. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.
Hyer R; McGuire DK; Xing B; Jackson S; Janssen R
Vaccine; 2018 May; 36(19):2604-2611. PubMed ID: 29628151
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.
Halperin SA; Dobson S; McNeil S; Langley JM; Smith B; McCall-Sani R; Levitt D; Nest GV; Gennevois D; Eiden JJ
Vaccine; 2006 Jan; 24(1):20-6. PubMed ID: 16198027
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years.
Hyer RN; Janssen RS
Vaccine; 2019 Sep; 37(39):5854-5861. PubMed ID: 31431412
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04.
Boland G; Beran J; Lievens M; Sasadeusz J; Dentico P; Nothdurft H; Zuckerman JN; Genton B; Steffen R; Loutan L; Van Hattum J; Stoffel M
Vaccine; 2004 Dec; 23(3):316-20. PubMed ID: 15530674
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
Cooper C; Mackie D
Expert Rev Vaccines; 2011 Apr; 10(4):417-27. PubMed ID: 21506639
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
[TBL] [Abstract][Full Text] [Related]
19. HBV-ISS (Dynavax).
Sung JJ; Lik-Yuen H
Curr Opin Mol Ther; 2006 Apr; 8(2):150-5. PubMed ID: 16610768
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis.
Onuigbo MA; Nesbit A; Weisenbeck J; Hurlburt J
Ren Fail; 2010 May; 32(4):531-2. PubMed ID: 20446799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
